XYF19 CAR-T cell therapy (Yufan/Abound Bio)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameXYF19 CAR-T cell therapy (Yufan/Abound Bio)
Drug Alias NameXYF19 CAR-T cellsAnti-CD19 CAR T-Cell Therapy (Yufan/Abound Bio)Anti-CD19 Autologous CAR T-Cell Therapy (Yufan Biotechnologies)Anti-CD19 CAR T-Cell Therapy (Yufan/Abound Bio)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsSplenic marginal zone lymphomaWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesXi'An Yufan Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXi'An Yufan Biotechnology Co LtdAbound Bio Inc
Inactive CompaniesN/A
Active IndicationsSplenic marginal zone lymphomaWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A